 Logo since 2015 | |
 Headquarters in Darmstadt, Germany | |
| Company type | Public |
|---|---|
| Industry | |
| Founded | 1668; 358 years ago (1668) |
| Founder | Friedrich Jacob Merck |
| Headquarters | , Germany |
Area served | Worldwide |
Key people |
|
| Products | Liquid crystals,life science and performance chemicals, Bioprocessing-Solutions,small molecules andbiopharmaceuticals |
| Revenue |  €21.16 billion (2024) |
| €3.645 billion (2024) | |
 €2.777 billion (2024) | |
| Total assets | €51.57 billion (2024) |
| Total equity | €29.99 billion (2024) |
| Owner |
|
Number of employees | 62,557 (2024) |
| Website | merckgroup |
| Footnotes / references [1][2][3][4][5] | |
TheMerck Group, branded and commonly known asMerck, is a Germanmultinational science and technology company headquartered inDarmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is MerckKGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.[6][7]
Merck operates inEurope,Africa,Asia,Oceania and theAmericas. It has majorresearch and development centres inDarmstadt,Boston,Tokyo andBeijing, as well as other Research and Development units inTaiwan,France,Israel,South Korea,India, and theUK.[8] Merck pioneered the commercial manufacture ofmorphine in the 19th century and for a time held a virtual monopoly oncocaine.
Merck was privately owned until going public on theFrankfurt Stock Exchange in 1995 and is listed on theDAX index of Germany's top companies. TheMerck family still controls a majority of 70.3% of the company's shares. The Merck Group includes around 250 companies in 180 countries; the current main parent company of the group, since 1995, is namedMerckKGaA, and is itself mainly owned by the former main parent company,E. MerckoHG, which now operates as aholding company.
The American pharmaceutical companyMerck & Co. was established as a subsidiary of Merck in 1891, but wasnationalized by the United States in 1917, before being privatized again whenGeorge W. Merck, a member of an American branch of the Merck family, repurchased the stock in 1919.[9] It is known as MSD (Merck Sharp and Dohme) outside of North America. The original Merck of Darmstadt holds the rights to the name Merck in all countries except the U.S. and Canada, where it is known as EMD (Emanuel Merck, Darmstadt), and the life science business specifically is known as MilliporeSigma. In 2015 Merck adopted a uniform brand identity for all its subsidiaries, and the company has stressed its intention to protect the brand of "the real Merck" globally and initiated litigation against its former subsidiary over use of the name.[10]
In 2018, the company celebrated their 350th anniversary.[11] Merck has formed a strategic alliance with theTechnische Universität Darmstadt, which is located in the same town as Merck.[12]
The roots of Merck reach back as far as the 17th century in theLandgraviate of Hesse-Darmstadt (now a part of Germany). In 1668,Friedrich Jacob Merck, anapothecary, assumed ownership of theEngel-Apotheke (lit. 'Angel Pharmacy') inDarmstadt.[citation needed]
In 1816,Emanuel Merck, a descendant of the original founder, took over the pharmacy. Thanks to his scientific education he was successful in isolating and characterizing several differentalkaloids in thepharmacy's laboratory, and by doing so also invented a number of drugs. He began the manufacture of these substances "in bulk" in 1827, touting them as a "Cabinet of Pharmaceutical and Chemical Innovations". He and his successors gradually built up achemical-pharmaceutical factory that produced — in addition to raw materials for pharmaceutical preparations — a multitude of other chemicals and (from 1890) medicines.[13]
In 1891, Georg(e) Merck established himself in the United States and set upMerck & Co. with Theodore Weicker in New York. Merck & Co. was confiscated following theFirst World War and set up as an independent company in the United States.[14][15] Today, the US company, which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, has about 68,000 employees (December 2021) in 120 countries. It is one of the top 5 pharmaceutical companies worldwide, larger than its German ancestor, which employs 60,334 people in 67 countries (December 2021). While Merck in Darmstadt is the legal successor of the original Merck and retains the rights to the name "Merck" in all countries except the U.S. and Canada, it is sometimes known as the "German Merck" or "Merck Darmstadt" in North America. The company was formerly also referred to as "E. Merck" (Emanuel Merck).[citation needed]
In the years of theNazi rule, the company was led by Karl Emanuel Merck who became a member of theNazi Party in 1933 and subsequently received the title ofWehrwirtschaftsführer. In addition, Merck was president of the Hessian Chamber of Commerce and Industry as well as performing an advisory function in the Expert Advisory Council for National Health ("Sachverständigenrat fürVolksgesundheit") of theNazi Party.[16] During World War II, Merck was manufacturing war essential products such as narcotics, vitamins,biocides and other chemicals. According to the company's account, 265forced laborers were working in the plant in Darmstadt, most of them women from Russia and Poland.[17] Additionally, several hundredFremdarbeiter ("foreign workers") from France and Belgium were employed throughout the war years. An air raid on 12 December 1944 destroyed nearly 70 percent of the plant and killed 55 employees.[18]
In 1973, Merck Ltd. acquired BDH Chemicals[19] from theGlaxo Group.
In the early 1980s Merck Group built a visitor center at its Darmstadt headquarters that featured a pyramid.[citation needed]
Merck was legally namedE. MerckoHG until 1995. In 1995 it was listed on theFrankfurt Stock Exchange and became aKGaA, legally namedMerck KGaA.[citation needed]
On 13 March 2006, Merck announced a takeover bid forSchering AG, the world's largest producer of oral contraceptives. On 23 March 2006,Bayer AG made a supported offer for Schering and Merck decided to drop out of the bidding for the company.[20] Schering is not to be confused withSchering-Plough which was once part of Schering AG but was acquired by Merck & Co. in 2009. In September 2006 the company announced a takeover bid of $13.2 billion forSerono SA, Switzerland's largest biotech firm. The deal included a buy-out of theBertarelli family's 64.5% stake in Serono to be followed by a public tender offer for the remaining shares starting in November 2006.[21][22] The combined company has an R&D budget of approximately $1.1 billion and sales of approximately $4.6 billion. Its approximately $2 billion in sales ofbiologics would make it seventh among pharmaceutical/biotech companies. The new entity,Merck Serono, began operations in 2007.
Merck KGaA established its philanthropic foundation in 2008 called Merck Foundation.Rasha Kelej currently serves as its CEO.[23][24]
In 2010, Merck took overBillerica (MA) basedMillipore Corporation for EUR 5.3 billion (US$7.2 billion).[25][26] It is now Merck's life science business unit. With the acquisition of Millipore, Merck is consolidating its US holdings and shutting down the Gibbstown facility and warehouse. Gibbstown operations will be transferred to the new Philadelphia office and Millipore headquarters.[27]
Merck Korea received the "Leading Investor Award" at the 5th Korea-EUIndustrial Cooperation Day in 2011.[citation needed]
In December 2013, the company boughtAZ Electronic Materials SA (AZEM) for about $2.6 billion in cash to increase its offering of specialty chemicals to the electronics industry.[28]
In September 2014 Merck halted the clinical development of two drug candidates in development withOxygen Biotherapeutics. One drug candidate suffered a lack of success inpatient recruitment, with its MUC1 antigen-specific cancerimmunotherapy drug,tecemotide (L-BLP25), missing its Phase I/II endpoint of increasing overall survival in patients with Stage IIInon-small cell lung cancer.[29] Later in September it was announced that the company would acquireSigma-Aldrich for $17 billion.[30] After the acquisition was completed in 2015, Merck had around 50,000 employees.[31] In November 2014, Merck andPfizer agreed a deal for the latter to sell the former sharing rights to develop an experimental immunotherapy drug for a fee of $850 million.[32]
In October 2015, Merck revealed it would return the rights of the Kuvan drug toBioMarin Pharmaceutical Inc. The drug is effective in the treatment of the rare genetic disorderPKU, however Merck is moving away from genetics intocancer treatment,immunology andneurology.[33] In October, it was announced thatKarl-Ludwig Kley, CEO of Merck since April 2007, would retire in April 2016, and be succeeded byStefan Oschmann, who has been a member of the executive board since 2011.[34] The company started building new facilities for its R&D operations and a new visitor center at its Darmstadt site in the early 2010s. By 2015 the site's pyramid had been torn down as part of the renovations.[35]
In April 2017, the company announced it had completed the acquisition of food safety testing company,BioControl Systems Inc.[36] In August of the same year the company announced the acquisition of Natrix Separations for an undisclosed sum.[37]
In April 2019, Merck announced it would acquireVersum Materials.[38] The acquisition was completed in October 2019 and represented an equity value of about U$5.8 billion.[39] In the same year, Merck has also announced the acquisition of Intermolecular Inc, the California-based company for advanced materials. The acquisition was completed in September 2019 and represented an equity value of U$62 million.[40]
In February 2020, Merck announced the divestment of its Allergopharma Business to Dermapharm, under an unspecified fee. The deal includes Merck's Portfolio in Europe and parts of Asia, including China and India.[41]
In January 2021,MilliporeSigma announced it would acquire AmpTec to expand and enhance the businesses mRNA vaccine capabilities as well as its treatment and diagnostics offerings.[42] In March, its Performance Materials division changed name to Electronics division.[43] In December of the same year, EMD Serono (Merck Group operations in the US and Canada) announced it would acquire Swiss-basedChord Therapeutics and its lead drugcladribine, used in generalisedmyasthenia gravis andneuromyelitis optica spectrum disorder.[44]
The company opened a large facility to support the semiconductor industry inKaohsiung in 2025.[45]
In September 2017, Merck said it is considering options for its consumer-health division, including a potential full or partial sale, or strategic partnership. Anequity analyst estimated the unit could command a purchase price of €1.8 billion to €2.7 billion from a full sale.[46] In DecemberReuters reported that bothNestlé and private equity owners ofStada[47] were preparing bids for Merck's consumer health group. Days later, Reuters again reported thatPerrigo was also preparing a bid for the division in the region of €4 billion ($4.7 billion to $4.8 billion).[48] In April 2018, Reuters reported that generic drug manufacturer,Mylan was in advanced discussions to acquire the consumer health business for between €3.5–4 billion (£3–3.4 billion).[49] Later in the month, Reuters reported thatProcter & Gamble would purchase the division for €3.4 billion euros (£2.96 billion; $4.2 billion).[50]
Merck in Darmstadt is the sole legal successor of the original Merck and retains the rights to the trademark "Merck" in all countries except the U.S. and Canada, where "EMD" brand is mostly used (it was introduced alongside Merck's 2001 logo[51]). In recent branding campaigns, the company has referred to itself as "the original Merck" and "the real Merck". The company was legally known asE. MerckoHG until 1995, whenMerckKGaA became the main parent company and the former aholding company. Both oHG and KGaA are generic business entity type designations and not used in everyday speech or branding.[citation needed]
In 2015 Merck adopted a new logo to increase the visual differences between both companies, while also visualizing "vibrant science and technology" as the new company's brand.[52] It has initiated litigation in several countries against its former subsidiaryMerck & Co. (MSD) over infringing use of the Merck name. In 2016, theHigh Court of Justice in the United Kingdom ruled that MSD had breached an agreement with its former parent company and that only Merck of Darmstadt is entitled to use the Merck name in the United Kingdom; the judge also held that MSD's use of "Merck" as part of branding on its global websites were directed to the UK and infringed Merck's trade mark rights in the UK.[53] In response, MSD has initiated counter-litigation in the United States.[54]
After those controversies, Merck also adopted a new logo for EMD. The same look was also given to the logos of EMD Serono, MilliporeSigma, and EMD Performance Materials (renamed EMD Electronics in March 2021) divisions. Its corporate website ismerckgroup.com in the world excluding U.S. and Canada, displaying normal Merck logo in the header, andemdgroup.com in U.S. and Canada, displaying use of its corporate name, Merck KGaA, Darmstadt, Germany, in the header and additionally displaying a disclaimer about trademark ownership in the footer.[citation needed]
On 7 December 2021, Merck, which uses the name EMD Electronics in North America, announced they would be investing $1 billion in a U.S. operations joint venture withPalantir Technologies to assist in solving some of the chip industries supply chain problems. The plan is for sites in Pennsylvania, Texas, California, and Arizona.[55]
Generics UK (Merck's former British subsidiary, the global Generics business being sold on 2 October 2007) paid a £12Mout-of-court settlement with theDepartment of Health and Social Care of the UK over involvement in an allegedprice and supply fixing cartel.[56]
TheNHS alleges various drugs companies exploited theoligopolistic market conditions, forcing the NHS to pay inflated prices. NHS fraud investigators believe there was aconspiracy to limit the supply of 30 of its most commonly prescribed drugs, including a class ofpenicillinantibiotics and to ageneric version of best-sellingulcer treatmentZantac.[57] The NHS has so far filed claims in relation to just three drugs, seeking damages of more than £150m, while theSerious Fraud Office (SFO) is conducting a parallel investigation into the price-fixing allegations limited to the supply of blood-thinning pillwarfarin andpenicillin-basedantibiotics. Homes and offices ofexecutives at six firms, includingRanbaxy, Generics UK,Norton Healthcare, Goldshield and Regent-GM were raided by the SFO in May 2002.[citation needed]
The following is an illustration of the company's mergers, acquisitions,spin-offs and historical predecessors:
Merck KGaA has faced criticism for continuing its business operations in Russia following the country's invasion of Ukraine. Despite international sanctions and pressure on companies to exit the Russian market, Merck KGaA has maintained its presence, citing commitments to supplying essential medicines. This decision has sparked backlash from activists and organizations advocating for corporate responsibility in geopolitical conflicts.[58]
After Wilhelm Adam Sertürner's isolation ofmorphine fromopium in 1805, Merck pioneered (from 1827) the commercial manufacture of morphine for an expanding global market. From 1884 onwards, Merck also played role in the production and marketing ofcocaine.Sigmund Freud, author ofÜber Coca (1884), was an enthusiastic collaborator in Merck's cocaine research, though the methodological sophistication of hisself-experimentation studies has been challenged.Attention was directed atvitamins as a newproduct category, andVigantol was introduced in 1927, followed by Cebion in 1934.[citation needed]
Following the defeat of Germany inWorld War II, Merck was granted permission by the military government to produce drugs, pesticides, food preservatives, reagents, and fine chemicals for laboratory use. Soon afterward the boom that is commonly known as the "Wirtschaftswunder" (economic miracle) set in. For Merck, this meant two-digit sales-growth figures for many years. Products of this time includedcorticoid preparations — for exampleFortecortin, which is still used today — the cold remedy Nasivin or the hormone preparations Gestafortin and Mantova.[citation needed]
Merck currently employs over 2,500 people in its 4 R&D hubs via.Boston,Darmstadt, Beijing and Tokyo.[59][60] In the year 2018, Merck invested over €1,6 billion in its R&D operations.[61]The focus of Merck's current pharmaceutical R&D is ononcology, neurology and immunology. In oncology, its first marketed product isErbitux (cetuximab), for which it has marketing rights worldwide, apart from North America.[62] (Cetuximab was discovered byImclone Systems, and is marketed in North America byBristol-Myers Squibb.) Other areas of Expertise from Merck Healthcare include Fertility, Endocrinology and General Medicine, the later focusing on treatments for Diabetes, Thyroid disease and Cardiovascular diseases. Some products from Merck includeMetformin,Bisoprolol,Levothyroxine andDigitoxin. Merck'sclinical research strategy consists of a partnership withQuintiles in which the latter helps the former in the clinical development of all its compounds.[63] In February 2019, Merck also announced a partnership with GSK to develop and commercialize M7824 (bintrafusp alfa*), a new Immunotherapy with potential in various difficult-to-treat cancers.[64] In 2020, Merck launched partnership withPechoin in China to develop "high-tech herbal"skincare products.[65]
The life science business of Merck, formerly known as Merck Millipore, was created in July 2010 following the completed acquisition of the US company Millipore. This division comprised all Millipore activities and major segments of the former Merck division Performance & Life Science Chemicals.[66]
In 2015, Merck acquiredSigma-Aldrich and combined it with Merck Millipore.[67] The company was branded Merck globally and MilliporeSigma in the United States and Canada[68] The science business of Merck/MilliporeSigma has 300,000 products and three business units: Life Science Services, Science & Lab Solutions, and Process Solutions. The Life Science Services include the Contract Development and Manufacturing Organization (CDMO) and contract testing services. Science & Lab Solutions includes products for Laboratories and Quality Control organizations. Process Solutions supports the biopharma manufacturing processes of its clients with single-use products.[69] The company has products organized under the brandsSigma-Aldrich, Millipore, SAFC, Supelco, Milli-Q, and Bioreliance.[70] The company serves customers in biotech, pharma, diagnostics, food safety, academia, and environmental. Jean-Charles Wirth serves as the CEO of the life science business of Merck.[71]
The Life Science business sponsors several award programs for graduate students. One of these awards, the Alfred R. Bader Award for Student Innovation recognizes advanced chemistry graduate students, typically in the field of synthetic organic chemistry.[citation needed]
Semiconductor Solutions is the largest business unit within Merck's Electronics business sector. It provides materials, delivery systems, and services for the semiconductor industry. The business unit supplies products for every major production step in the wafer processing, including doping, lithography, patterning, deposition, planarization, etching, and cleaning. After the acquisition of Intermolecular, its capabilities allow material combinations to be tested directly in the specific application environment accelerating learning cycles. Since the acquisition of Versum and Intermolecular, inc., the company's portfolio in electronic materials was significantly expanded. The launch of the integrated organization was done on 1 June 2020.[citation needed]
Merck started working on effect pigments in 1957. The business unit is called Surface Solutions. The core markets for Surface Solutions are automotive coatings, cosmetics, and, to a smaller extent, industrials. An example of its pigments is alumina effect pigments sold under the brand nameXirallic. Currently, this business unit pools all activities for pigments in lacquering, printing, and plastic applications, in the field of security technology (for instance counterfeiting protection), pigments for applications in the food and pharmaceutical areas, functional materials, and active substances and pigments for cosmetics.[citation needed]
M Ventures is aventure capital fund of Merck. In 2021, the funds available for investment were increased by Eur 600M to enable investments Biotechnology and Technology.[72]
The award was jointly established by Merck and theTechnische Universität Darmstadt in 1992. It recognizes scientists who have made contributions to chemical and pharmaceutical research.[73]
The award was established in 1988 to recognize novel methods in analytical chemistry. Since 2025, the scope of the award has been broadened to encompass innovation in the computational sciences.[74]
During the company's 350th anniversary in 2018, Merck announced theFuture Insight Prize. The prize consists of a research grant of €1,000,000 ($1.1 million) every year through the next 35 years, to motivate innovation in areas that could solve humanity's most pressing issues.[75]
Merck is celebrating its 350th anniversary. The theme of the celebration will be "Always curious – Imagine the next 350 years".
I am of the opinion, however, that indirect ownership of this kind cannot be recognized under the Trading-with-the-Enemy Act, and I have, therefore, determined that the whole of this stock is enemy owned and it has accordingly been taken over.
{{cite news}}:|archive-url= is malformed: timestamp (help)CS1 maint: url-status (link)
| International | |
|---|---|
| National | |
| Other | |
